Co-administration of an α(1) -blocker improves the efficacy and safety of antimuscarinic agents in rats with detrusor overactivity - Abstract

Department of Urology, Faculty of Medical Science, University of Fukui, Eiheiji, Fukui, Japan.


To investigate the efficacy and safety of a combination treatment with α(1) -blockers and antimuscarinics for detrusor overactivity in rats.

Rats with detrusor overactivity caused by a cerebral infarction were divided into four groups that received an i.v. administration of tamsulosin (0.1-1000 µg/kg); solifenacin (0.01-0.3 mg/kg); combined low doses of tamsulosin (0.008, 0.1 µg/kg) and solifenacin (0.01 mg/kg); or solifenacin (0.1, 0.3, 1.0 mg/kg) at 1-h intervals during the continuous administration of tamsulosin (0.01 µg/kg/h).

Both tamsulosin alone and solifenacin alone significantly increased bladder capacity in cerebral infarcted rats, but these effects were reduced in rats pretreated with resiniferatoxin. The combined low dose of tamsulosin and solifenacin resulted in a significant increase in bladder capacity compared to mono-administration of 0.01 mg/kg solifenacin (68.8 vs 19.8% of control value, respectively). In the group receiving solifenacin at 1-h intervals, solifenacin dose-dependently decreased bladder contraction duration and a significant reduction in bladder contraction pressure (by 35.0% of control value) was found at the highest dose (1.0 mg/kg). However, no reduction in bladder contraction duration was found even at the highest dose of solifenacin when co-administered with tamsulosin.

α1 -blockers and antimuscarinic agents have an additive ameliorative effect on detrusor overactivity when co-administered at low doses. α1 -blockers prevent the reduction in bladder contraction duration induced by a high-dose administration of antimuscarinic agents.

Written by:
Nagase K, Ito H, Aoki Y, Tanase K, Akino H, Yokoyama O.   Are you the author?

Reference: Int J Urol. 2011 Oct 13. Epub ahead of print.
doi: 10.1111/j.1442-2042.2011.02868.x

PubMed Abstract
PMID: 21995543 Investigational Urology Section


email news signup